TENX Stock Overview
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tenax Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$61.20 |
| 52 Week Low | US$3.48 |
| Beta | 2.27 |
| 1 Month Change | -5.41% |
| 3 Month Change | -66.81% |
| 1 Year Change | -86.58% |
| 3 Year Change | -99.89% |
| 5 Year Change | -99.87% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| TENX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | 1.5% | 1.2% |
| 1Y | -86.6% | 1.1% | 24.7% |
Return vs Industry: TENX underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: TENX underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| TENX volatility | |
|---|---|
| TENX Average Weekly Movement | 25.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TENX's share price has been volatile over the past 3 months.
Volatility Over Time: TENX's weekly volatility has decreased from 46% to 25% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 6 | Chris Giordano | www.tenaxthera.com |
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. Fundamentals Summary
| TENX fundamental statistics | |
|---|---|
| Market cap | US$6.85m |
| Earnings (TTM) | -US$7.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs TENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TENX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.71m |
| Earnings | -US$7.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.2% |
How did TENX perform over the long term?
See historical performance and comparison